Barr's Pliva Acquisition To Boost CEE Generics

US firm Barr Pharmaceuticals is set to acquire Croatia generic company Pliva for US$2.2bn, which will create a powerful, global pharmaceutical company that has its sights on the booming Central and Eastern European (CEE) generics market among other targets.

To read the full article, please choose one of the following options: